Literature DB >> 8631046

Effects of intravenous disopyramide on coronary hemodynamics and vasodilator reserve in hypertrophic obstructive cardiomyopathy.

M Hongo1, T Nakatsuka, H Takenaka, M Tanaka, N Watanabe, Y Yazaki, M Sekiguchi.   

Abstract

Disopyramide reduces the subaortic pressure gradients and improves the clinical symptoms of patients with hypertrophic obstructive cardiomyopathy. Changes in coronary hemodynamics and vasodilator reserve in response to this agent have not been evaluated in such patients. To assess the acute effects of intravenous administration of disopyramide on coronary hemodynamics, microvascular dilatory capacity, and balance between myocardial oxygen supply and demand in hypertrophic obstructive cardiomyopathy, we examined 12 patients using an intravascular Doppler catheter and spectral analysis. Intravenous disopyramide 100 mg over 10 min caused mild increases in heart rate and aortic systolic pressure and a significant fall in left ventricular systolic pressure, resulting in a 13% decrease in the product of heart rate and left ventricular systolic pressure (from 1.13 +/- 0.18 x 10(4) before disopyramide to 0.98 +/- 0.17 x 10(4) beats/min x mm Hg 10 min afterwards; p < 0.05) and a reduction in the resting peak systolic pressure gradients of the left ventricular outflow tract. There was a 14% reduction in coronary blood flow (from 93.5 +/- 13.2 to 80.3 +/- 11.6 ml/min; p < 0.05) with an increase in coronary resistance (from 0.94 +/- 0.16 to 1.23 +/- 0.21 mm Hg/ml/min; p < 0.001). The index of coronary vasodilator reserve remained unchanged. These findings suggest that intravenous disopyramide causes a coronary vasoconstrictive effect without significantly changing the coronary microvascular dilatory capacity, but this effect may not be harmful to the balance between myocardial oxygen supply and demand in patients with hypertrophic obstructive cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8631046     DOI: 10.1159/000177052

Source DB:  PubMed          Journal:  Cardiology        ISSN: 0008-6312            Impact factor:   1.869


  5 in total

Review 1.  Medical treatment of hypertrophic cardiomyopathy.

Authors:  M V Sherrid; D Gunsburg; A Sharma
Journal:  Curr Cardiol Rep       Date:  2000-03       Impact factor: 2.931

2.  Cibenzoline improves coronary flow velocity reserve in patients with hypertrophic obstructive cardiomyopathy.

Authors:  Tai Sekine; Masao Daimon; Rei Hasegawa; Kiyomi Teramoto; Takayuki Kawata; Nobuhiro Tanaka; Yasuhiro Takei; Kenji Takazawa; Katsuya Yoshida; Issei Komuro
Journal:  Heart Vessels       Date:  2006-11-27       Impact factor: 2.037

3.  Disopyramide improves the balance between myocardial oxygen supply and demand in patients with hypertrophic obstructive cardiomyopathy.

Authors:  K Niki; M Sugawara; R Asano; T Oka; Y Kondoh; S Tanino; K Iwade; N Magosaki; H Kasanuki; S Hosoda
Journal:  Heart Vessels       Date:  1997       Impact factor: 2.037

Review 4.  Coronary microvascular dysfunction: an update.

Authors:  Filippo Crea; Paolo G Camici; Cathleen Noel Bairey Merz
Journal:  Eur Heart J       Date:  2013-12-23       Impact factor: 29.983

5.  Effects of flecainide on left ventricular pressure gradient and symptoms in obstructive hypertrophic cardiomyopathy: a comparison of flecainide and disopyramide.

Authors:  Shintaro Haruki; Yuichiro Minami; Atsushi Suzuki; Nobuhisa Hagiwara
Journal:  Heart Vessels       Date:  2014-06-12       Impact factor: 2.037

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.